CPMI has a 30-year history of providing its clients with unique capabilities, executing on complex trials in normal healthy volunteers and highly specialized populations. Well known for its ability to enroll in studies targeting renal insufficiency, hepatic impairment, T2DM, dermatology, elderly healthy subjects, post-menopausal women, sexual dysfunction (male and female), smoking cessation and obesity, CPMI continues to expand into new indications. The 120-bed Phase I unit is a preferred site for many large pharmaceutical sponsors, biotechnology and specialty pharmaceutical companies. Additionally, several clinical research organization clients trust CPMI’s established team to deliver when their own Phase I units are at capacity or a multi-center approach is needed. With veterans Dr. Kenneth Lasseter, Stacy Dilzer and Cooper Shamblen leading the team, CPMI has successfully completed hundreds of FIM, PK/PD, SAD/MAD, DDI, TQT, food effect, and BA/BE studies. Evolution Research Group’s service offering is greatly enhanced by CPMI’s clinical pharmacology expertise, enabling Evolution Research Group to meet its clients’ needs throughout the lifecycle of a compound’s development. The CPMI Research Unit and location was carefully considered. Our facility was meticulously custom designed and constructed, employing all the knowledge of our experience. We are convinced that our 120 bed research unit is “State of the Art”. We are equipped with the experience, expertise and the research unit facility to meet the individual needs of each sponsor and research protocol.